KORU Medical Systems (NASDAQ:KRMD – Get Free Report) and Arch Therapeutics (OTCMKTS:ARTH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, risk and dividends.
Profitability
This table compares KORU Medical Systems and Arch Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| KORU Medical Systems | -4.03% | -10.83% | -6.51% |
| Arch Therapeutics | -8,257.70% | N/A | -730.22% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for KORU Medical Systems and Arch Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| KORU Medical Systems | 1 | 0 | 4 | 0 | 2.60 |
| Arch Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Insider & Institutional Ownership
58.6% of KORU Medical Systems shares are held by institutional investors. Comparatively, 6.9% of Arch Therapeutics shares are held by institutional investors. 18.5% of KORU Medical Systems shares are held by insiders. Comparatively, 4.5% of Arch Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Volatility and Risk
KORU Medical Systems has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 4.02, meaning that its share price is 302% more volatile than the S&P 500.
Valuation & Earnings
This table compares KORU Medical Systems and Arch Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| KORU Medical Systems | $41.13 million | 3.98 | -$2.64 million | ($0.05) | -71.20 |
| Arch Therapeutics | $80,000.00 | 9.53 | -$6.98 million | ($2.34) | -0.07 |
KORU Medical Systems has higher revenue and earnings than Arch Therapeutics. KORU Medical Systems is trading at a lower price-to-earnings ratio than Arch Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
KORU Medical Systems beats Arch Therapeutics on 10 of the 14 factors compared between the two stocks.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
About Arch Therapeutics
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.
Receive News & Ratings for KORU Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KORU Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
